Cargando…
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease
BACKGROUND: Fistulizing Crohn's disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal. Mycobacterium avium ss paratuberculosis (MAP) treatment in CD is gaining attention. AIM: We evaluated healing of CD fistula(e) using a novel combination therapy. STUDY: N...
Autores principales: | Agrawal, Gaurav, Borody, Thomas, Turner, Robert, Leis, Sharyn, Campbell, Jordana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137971/ https://www.ncbi.nlm.nih.gov/pubmed/28031926 http://dx.doi.org/10.4155/fso.15.77 |
Ejemplares similares
-
Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020) -
Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022) -
Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
por: Ma, Ye, et al.
Publicado: (2023) -
Evaluating the effectiveness of infliximab on perianal fistulizing Crohn’s disease by magnetic resonance imaging
por: Yan, Xiaohan, et al.
Publicado: (2019) -
Fistulizing Crohn’s Disease
por: Scharl, Michael, et al.
Publicado: (2017)